Patents by Inventor Alessandro Rolfo

Alessandro Rolfo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conditioned medium obtained from placental mesenchymal stem cells and use thereof in the therapeutic treatment of preeclampsia
    Patent number: 10413573
    Abstract: The present invention relates to a conditioned medium (CM) which is obtained by culturing, in a liquid culture medium, placental mesenchymal stem cells isolated from the placental tissue of pregnant women who not affected by preeclampsia. The conditioned medium of the present invention includes at least IL-6, IL-8 and MCP-1 proteins. The conditioned medium of the present invention is effective for the therapeutic treatment of preeclampsia.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 17, 2019
    Assignee: Corion Biotech S.R.L.
    Inventors: Alessandro Rolfo, Tullia Todros
  • Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour
    Patent number: 9943548
    Abstract: It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells from a preeclamptic placenta. The conditioned medium object of the invention includes at least IP-10 and TARC proteins and it is used for the therapeutic treatment of a tumor, preferably an epithelial tumor.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: April 17, 2018
    Assignee: Corion Biotech S.R.L.
    Inventors: Alessandro Rolfo, Tullia Todros
  • CONDITIONED MEDIUM OBTAINED FROM PLACENTAL MESENCHYMAL STEM CELLS AND USE THEREOF IN THE THERAPEUTIC TREATMENT OF PREECLAMPSIA
    Publication number: 20170216366
    Abstract: The present invention relates to a conditioned medium (CM) which is obtained by culturing, in a liquid culture medium, placental mesenchymal stem cells isolated from the placental tissue of pregnant women who not affected by preeclampsia. The conditioned medium of the present invention includes at least IL-6, IL-8 and MCP-1 proteins. The conditioned medium of the present invention is effective for the therapeutic treatment of preeclampsia.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 3, 2017
    Applicant: CORION BIOTECH S.r.l.
    Inventors: Alessandro ROLFO, Tullia TODROS
  • Preeclamptic Placental Mesenchymal Stem Cell Conditioned Medium for Use in the Treatment of a Tumour
    Publication number: 20150250823
    Abstract: It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells from a preeclamptic placenta. The conditioned medium object of the invention includes at least IP-10 and TARC proteins and it is used for the therapeutic treatment of a tumor, preferably an epithelial tumor.
    Type: Application
    Filed: October 2, 2013
    Publication date: September 10, 2015
    Applicant: CORION BIOTECH S/r.L.
    Inventors: Alessandro Rolfo, Tullia Todros
  • CONDITIONED MEDIUM OBTAINED FROM PLACENTAL MESENCHYMAL STEM CELLS AND USE THEREOF IN THE THERAPEUTIC TREATMENT OF PREECLAMPSIA
    Publication number: 20150017122
    Abstract: It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells isolated from the placental tissue of pregnant women not affected by preeclampsia. The conditioned medium of the invention includes at least IL-6, IL-10 and MCP-1 proteins and it is effective for the therapeutic treatment of preeclampsia.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 15, 2015
    Applicant: CORION BIOTECH S.R.L.
    Inventors: Alessandro Rolfo, Tullia Todros
  • DIAGNOSTIC COMPOSITIONS AND TREATMENT METHODS FOR CONDITIONS INVOLVING TROPHOBLAST CELL DEATH, DIFFERENTIATION, INVASION AND/OR CELL FUSION AND TURNOVER
    Publication number: 20090246773
    Abstract: The invention provides a method for diagnosing in a subject a condition requiring modulation of or involving trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, comprising detecting HIF I? and the factors which modulate or are modulated by this protein, specifically TGF?3, sFLT, VEGF, SMAD2, 3 and 7, MtdP, MtdL, MclI 1, MclIc, VHL, SiahI, Siah2, ENG, and PHD. The invention also provides a method for diagnosing or distinguishing in a subject a specific condition requiring modulation of or involving trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, in particular early onset severe preeclampsia (EPE), late onset preeclampsia (LPE) and mtre-uterme growth restriction (IUGR) comprising detecting HLF I? and the factors which modulate or are modulated by this protein as defined above.
    Type: Application
    Filed: March 9, 2007
    Publication date: October 1, 2009
    Applicant: Mount Sinai Hospital
    Inventors: Isabella Caniggia, Alessandro Rolfo, Martin Post